Pdi Inc (PDII) 1.84 $PDII
PDI, Inc. Subsidiary Interpace Diagnostics Announces PancraGen(TM) Benefits Reinforced in Pivotal Study Published in Endoscopy
PR Newswire - Wed Feb 04, 7:35AM CST
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today the publication of results of the pivotal PancraGen(TM) multicenter clinical validation study in the February 2015 issue of Endoscopy.i The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients' likelihood of pancreatic cancer. These results provide support for using PancraGen to provide more informed management decisions for patients with pancreatic cysts, including whether surgery or surveillance is the most appropriate approach.
PDII: 1.84 (+0.11)
PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX(TM) Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules
PR Newswire - Wed Dec 17, 7:58AM CST
PDI, Inc. (Nasdaq: PDII) today announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX(TM) test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. Over 525,000 thyroid FNA's (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate. ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.
PDII: 1.84 (+0.11)
Insider Trading Alert - PDII, SSI And FBIZ Traded By Insiders
at The Street - Wed Nov 26, 1:00PM CST
Stocks with insider trader activity include PDII, SSI and FBIZ
SSI: 21.99 (+1.14), PDII: 1.84 (+0.11), FBIZ: 46.60 (+0.47)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 11:49AM CST
MPET: 0.84 (-0.03), EOPN: 8.55 (-0.01), AVAV: 26.86 (+0.37), NRX: 6.67 (-0.14), VSR: 3.42 (-0.02), MCOX: 3.96 (-0.06), SDRL: 12.32 (-0.70), NADL: 2.10 (-0.02), PDII: 1.84 (+0.11), CUB: 52.32 (+0.09), HKTV: 8.00 (+0.06), SOL: 1.40 (-0.07), VEEV: 30.12 (+0.17), DO: 35.21 (+0.36), IDRA: 4.10 (-0.14), TITN: 14.01 (+0.17), VGGL: 1.77 (-0.08), HART: 2.92 (+0.34), LIQD: 0.38 (+0.01), CTRP: 46.75 (+0.11)
Digirad: Management Did A Much Better Job Than I Thought
Bram de Haas - at Seeking Alpha - Wed Nov 26, 8:48AM CST
DRAD: 4.50 (+0.08), PDII: 1.84 (+0.11)
Boyd Coddington's Garage(R) Launches Specialty Automotive Car Care Line And Brings Professional Detailing Products to Consumers
PRWeb - Tue Nov 25, 2:03AM CST
"We are proud of all of the products and feel the auto retail marketplace is an ideal arena for us to introduce the Boyd's brand name to a new consumer audience." Said Boyd Coddington, Jr. "Our research and development, coupled with our partnerships with the industry's top professional detailers, has resulted in some of the best products available anywhere in the world. I am excited about the growth potential."
PDII: 1.84 (+0.11)
Nasdaq stocks posting largest volume increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
SFST: 17.20 (-0.42), ORBC: 5.83 (+0.21), MFLX: 14.99 (+0.16), ESSX: 1.14 (+0.02), PDII: 1.84 (+0.11), PLNR: 6.63 (-0.07), SZYM: 2.64 (+0.02)
PDI's (PDII) CEO Nancy Lurker on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:48AM CST
PDII: 1.84 (+0.11)
PDI misses by $0.10, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:23AM CST
PDII: 1.84 (+0.11)
PDI Expands Molecular Diagnostics Business with RedPath Integrated Pathology Acquisition
PR Newswire - Mon Nov 03, 5:00AM CST
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the acquisition of RedPath Integrated Pathology, a molecular diagnostics company helping physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG® platform. The acquisition immediately expands the oncology diagnostic product portfolio for PDI, Inc. subsidiary, Interpace Diagnostics, with a test currently generating approximately $10 million in revenue that is marketed for determining pancreatic cancer risk from pancreatic cysts, as well as tests in late-stage development for assessing cancer risk for Barrett's esophagus and in the biliary tract.
PDII: 1.84 (+0.11)
PDI, Inc. Announces Date & Time Change for Third Quarter Financial Results Conference Call
PR Newswire - Fri Oct 31, 7:00AM CDT
PDI, Inc. (Nasdaq
DII) today announced that it has adjusted the date and time it will release its third quarter 2014 financial results and operational highlights. The company will now release its results on Monday, November 3, 2014 and will host a conference call on Monday, November 3 at 8:00 a.m. Eastern Time to discuss the results.
PDII: 1.84 (+0.11)
Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company
PR Newswire - Fri Oct 31, 7:00AM CDT
Digirad Corporation (Nasdaq: DRAD) today announced that it has sent a letter to PDI, Inc. (Nasdaq: PDII), a healthcare commercialization services company, responding to PDI's summary rejection of Digirad's proposal to acquire the company.
PDII: 1.84 (+0.11), DRAD: 4.50 (+0.08)
John Climaco Resigns from PDI's Board of Directors
PR Newswire - Thu Oct 30, 8:24AM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced today that John Climaco has resigned from its board of directors effective October 29, 2014. He served in this role since October 2013.
PDII: 1.84 (+0.11)
PDI, Inc. Confirms Receipt of Unsolicited Acquisition Proposal from Digirad Corporation
PR Newswire - Thu Oct 30, 7:30AM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, has responded to the letter dated October 29, 2014 from Digirad Corporation regarding Digirad's willingness to offer to acquire PDI by indicating that PDI is not for sale and does not view Digirad's letter to be a meaningful offer to acquire PDI.
PDII: 1.84 (+0.11)
Digirad Delivers Letter To PDI, Inc. Expressing Willingness To Acquire Company At A Premium To Market For A Combination Of Cash And Stock Of Digirad
PR Newswire - Wed Oct 29, 4:26PM CDT
Digirad Corporation (Nasdaq: DRAD) today announced that it has sent a letter to PDI, Inc. (Nasdaq: PDII), a healthcare commercialization services company, expressing its willingness to acquire the company, through an appropriate acquisition entity by merger or otherwise, for a premium to PDI's current market price, to be determined after due diligence and discussions with the company. Digirad anticipates the consideration would be comprised of cash and stock of Digirad at a ratio to be determined at a later date.
PDII: 1.84 (+0.11), DRAD: 4.50 (+0.08)
PDI, Inc. to Hold Third Quarter Financial Results Conference Call on Tuesday, November 4, 2014
PR Newswire - Mon Oct 27, 8:00AM CDT
PDI, Inc. (Nasdaq: PDII) today announced that it will release its third quarter 2014 financial results and operational highlights on Monday, November 3, 2014 after the market close and host a conference call on Tuesday, November 4 at 8:30 am Eastern time to discuss the results.
PDII: 1.84 (+0.11)
PDI, Inc. Announces Appointment of Graham G. Miao, MBA, Ph.D. as Chief Financial Officer
PR Newswire - Tue Oct 14, 4:31PM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the appointment of Graham G. Miao, MBA, Ph.D., as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), responsible for overseeing the company's financial and operational management to help drive its healthcare commercialization services and molecular diagnostics businesses. He will report to Nancy Lurker, PDI's Chief Executive Officer, and begin his new role on October 20, 2014.
PDII: 1.84 (+0.11), DCTH: 1.14 (+0.04)
PDII, SVM, GTE Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Oct 02, 4:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PDI Inc (NASDAQ DII), Silvercorp Metals Inc (NYSE:SVM), GRAN TIERRA ENERGY INC (NYSE:GTE) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PDII: 1.84 (+0.11), GTE: 2.83 (+0.08), SVM: 1.38 (+0.04)
PDI Inc. Posts Wider-Than-Expected Loss, Reiterates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:50AM CDT
PDI, Inc. (PDII) posted second-quarter 2014 operating loss of 17 cents per share that was wider than the Zacks Consensus Estimate of 12 cents per share.
SFUN: 6.74 (-0.01), PDII: 1.84 (+0.11), CATM: 37.02 (-0.37), VVI: 26.22 (+0.26)
PDI, Inc. Subsidiary Interpace Diagnostics Announces PancraGen(TM) Benefits Reinforced in Pivotal Study Published in Endoscopy
PR Newswire - Wed Feb 04, 7:35AM CST
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today the publication of results of the pivotal PancraGen(TM) multicenter clinical validation study in the February 2015 issue of Endoscopy.i The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients' likelihood of pancreatic cancer. These results provide support for using PancraGen to provide more informed management decisions for patients with pancreatic cysts, including whether surgery or surveillance is the most appropriate approach.
PDII: 1.84 (+0.11)
PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX(TM) Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules
PR Newswire - Wed Dec 17, 7:58AM CST
PDI, Inc. (Nasdaq: PDII) today announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX(TM) test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. Over 525,000 thyroid FNA's (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate. ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.
PDII: 1.84 (+0.11)
Insider Trading Alert - PDII, SSI And FBIZ Traded By Insiders
at The Street - Wed Nov 26, 1:00PM CST
Stocks with insider trader activity include PDII, SSI and FBIZ
SSI: 21.99 (+1.14), PDII: 1.84 (+0.11), FBIZ: 46.60 (+0.47)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 11:49AM CST
MPET: 0.84 (-0.03), EOPN: 8.55 (-0.01), AVAV: 26.86 (+0.37), NRX: 6.67 (-0.14), VSR: 3.42 (-0.02), MCOX: 3.96 (-0.06), SDRL: 12.32 (-0.70), NADL: 2.10 (-0.02), PDII: 1.84 (+0.11), CUB: 52.32 (+0.09), HKTV: 8.00 (+0.06), SOL: 1.40 (-0.07), VEEV: 30.12 (+0.17), DO: 35.21 (+0.36), IDRA: 4.10 (-0.14), TITN: 14.01 (+0.17), VGGL: 1.77 (-0.08), HART: 2.92 (+0.34), LIQD: 0.38 (+0.01), CTRP: 46.75 (+0.11)
Digirad: Management Did A Much Better Job Than I Thought
Bram de Haas - at Seeking Alpha - Wed Nov 26, 8:48AM CST
DRAD: 4.50 (+0.08), PDII: 1.84 (+0.11)
Boyd Coddington's Garage(R) Launches Specialty Automotive Car Care Line And Brings Professional Detailing Products to Consumers
PRWeb - Tue Nov 25, 2:03AM CST
"We are proud of all of the products and feel the auto retail marketplace is an ideal arena for us to introduce the Boyd's brand name to a new consumer audience." Said Boyd Coddington, Jr. "Our research and development, coupled with our partnerships with the industry's top professional detailers, has resulted in some of the best products available anywhere in the world. I am excited about the growth potential."
PDII: 1.84 (+0.11)
Nasdaq stocks posting largest volume increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
SFST: 17.20 (-0.42), ORBC: 5.83 (+0.21), MFLX: 14.99 (+0.16), ESSX: 1.14 (+0.02), PDII: 1.84 (+0.11), PLNR: 6.63 (-0.07), SZYM: 2.64 (+0.02)
PDI's (PDII) CEO Nancy Lurker on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:48AM CST
PDII: 1.84 (+0.11)
PDI misses by $0.10, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:23AM CST
PDII: 1.84 (+0.11)
PDI Expands Molecular Diagnostics Business with RedPath Integrated Pathology Acquisition
PR Newswire - Mon Nov 03, 5:00AM CST
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the acquisition of RedPath Integrated Pathology, a molecular diagnostics company helping physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG® platform. The acquisition immediately expands the oncology diagnostic product portfolio for PDI, Inc. subsidiary, Interpace Diagnostics, with a test currently generating approximately $10 million in revenue that is marketed for determining pancreatic cancer risk from pancreatic cysts, as well as tests in late-stage development for assessing cancer risk for Barrett's esophagus and in the biliary tract.
PDII: 1.84 (+0.11)
PDI, Inc. Announces Date & Time Change for Third Quarter Financial Results Conference Call
PR Newswire - Fri Oct 31, 7:00AM CDT
PDI, Inc. (Nasdaq
DII) today announced that it has adjusted the date and time it will release its third quarter 2014 financial results and operational highlights. The company will now release its results on Monday, November 3, 2014 and will host a conference call on Monday, November 3 at 8:00 a.m. Eastern Time to discuss the results. PDII: 1.84 (+0.11)
Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company
PR Newswire - Fri Oct 31, 7:00AM CDT
Digirad Corporation (Nasdaq: DRAD) today announced that it has sent a letter to PDI, Inc. (Nasdaq: PDII), a healthcare commercialization services company, responding to PDI's summary rejection of Digirad's proposal to acquire the company.
PDII: 1.84 (+0.11), DRAD: 4.50 (+0.08)
John Climaco Resigns from PDI's Board of Directors
PR Newswire - Thu Oct 30, 8:24AM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced today that John Climaco has resigned from its board of directors effective October 29, 2014. He served in this role since October 2013.
PDII: 1.84 (+0.11)
PDI, Inc. Confirms Receipt of Unsolicited Acquisition Proposal from Digirad Corporation
PR Newswire - Thu Oct 30, 7:30AM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, has responded to the letter dated October 29, 2014 from Digirad Corporation regarding Digirad's willingness to offer to acquire PDI by indicating that PDI is not for sale and does not view Digirad's letter to be a meaningful offer to acquire PDI.
PDII: 1.84 (+0.11)
Digirad Delivers Letter To PDI, Inc. Expressing Willingness To Acquire Company At A Premium To Market For A Combination Of Cash And Stock Of Digirad
PR Newswire - Wed Oct 29, 4:26PM CDT
Digirad Corporation (Nasdaq: DRAD) today announced that it has sent a letter to PDI, Inc. (Nasdaq: PDII), a healthcare commercialization services company, expressing its willingness to acquire the company, through an appropriate acquisition entity by merger or otherwise, for a premium to PDI's current market price, to be determined after due diligence and discussions with the company. Digirad anticipates the consideration would be comprised of cash and stock of Digirad at a ratio to be determined at a later date.
PDII: 1.84 (+0.11), DRAD: 4.50 (+0.08)
PDI, Inc. to Hold Third Quarter Financial Results Conference Call on Tuesday, November 4, 2014
PR Newswire - Mon Oct 27, 8:00AM CDT
PDI, Inc. (Nasdaq: PDII) today announced that it will release its third quarter 2014 financial results and operational highlights on Monday, November 3, 2014 after the market close and host a conference call on Tuesday, November 4 at 8:30 am Eastern time to discuss the results.
PDII: 1.84 (+0.11)
PDI, Inc. Announces Appointment of Graham G. Miao, MBA, Ph.D. as Chief Financial Officer
PR Newswire - Tue Oct 14, 4:31PM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the appointment of Graham G. Miao, MBA, Ph.D., as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), responsible for overseeing the company's financial and operational management to help drive its healthcare commercialization services and molecular diagnostics businesses. He will report to Nancy Lurker, PDI's Chief Executive Officer, and begin his new role on October 20, 2014.
PDII: 1.84 (+0.11), DCTH: 1.14 (+0.04)
PDII, SVM, GTE Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Oct 02, 4:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PDI Inc (NASDAQ
DII), Silvercorp Metals Inc (NYSE:SVM), GRAN TIERRA ENERGY INC (NYSE:GTE) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: PDII: 1.84 (+0.11), GTE: 2.83 (+0.08), SVM: 1.38 (+0.04)
PDI Inc. Posts Wider-Than-Expected Loss, Reiterates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:50AM CDT
PDI, Inc. (PDII) posted second-quarter 2014 operating loss of 17 cents per share that was wider than the Zacks Consensus Estimate of 12 cents per share.
SFUN: 6.74 (-0.01), PDII: 1.84 (+0.11), CATM: 37.02 (-0.37), VVI: 26.22 (+0.26)
